[ACN Newswire] – Medgenics’ (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboardSee who Gilead is hiring next, click here to view […]
[ACN Newswire] – By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingWith Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Ivan DeryuginThe past few months have been eventful ones for Biogen Idec (NASDAQ:BIIB), as the company awaits the FDA’s decision on BG-12 and continues to build out is pipeline. Last week, Biogen reported … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingHepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, it may soon … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David SobekIn November of 2011, Gilead (NASDAQ:GILD) announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO John Martin noted , the … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingChalk another nuc up to the FDA’s growing list of safety-related development interruptions. On Tuesday, BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that it has withdrawn an … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Ivan DeryuginThe biotechnology sector can be broken up, at its simplest, into two distinct groups: the Big 4, and every other company. The Big 4 are Amgen (NASDAQ:AMGN), Celgene (NASDAQ:CELG), Gilead … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]
